Received: 24 December 2019; Published on-line: 21 February 2020

Predicting post-surgical recurrent diabetic maculopathy in patients with type 2 diabetes mellitus

Iu.O. Panchenko1, Cand Sc (Med); S.Yu. Mogilevskyy2, Dr Sc (Med), Prof.;  S.V. Ziablitsev3, Dr Sc (Med), Prof

1 Kyiv Municipal Clinical Hospital “Eye Microsurgery Center”;  Kyiv (Ukraine)

2 Shupik National Medical Academy of Postgraduate Education; Kyiv (Ukraine)

3 Bohomolets National Medical University;Kyiv (Ukraine)

E-mail: sergey.mogilevskyy@gmail.com

TO CITE THIS ARTICLE: Panchenko IuO, Mogilevskyy SYu, Ziablitsev SV. Predicting post-surgical recurrent diabetic maculopathy in patients with type 2 diabetes mellitus. J.ophthalmol.(Ukraine).2020;1:3-9. http://doi.org/10.31288/oftalmolzh2020139


Background: A closed subtotal vitrectomy (CSV), either alone or in combinations with internal limiting membrane (ILM) peeling, panretinal laser coagulation (PRLC); and cataract phacoemulsification (phaco) is a common treatment for diabetic maculopathy (DMP). Predicting post-surgical recurrent DMP in patients with type 2 diabetes mellitus (T2DM) based on identified pathogenetic factors for T2DM, and genotyping, medical history and clinical findings is a challenge.

Purpose: To develop a model for predicting post-surgical recurrent DMP in patients with T2DM.

Material and Methods: The study included 313 patients with T2DM (313 eyes) and DMP. Patients received one of the four types of surgical treatment: only a 25+ three-port CSTV (n=78); CSTV combined ILM peeling in a 2.5 mm- to 3.5-mm diameter macular area (n=85); CSTV combined with ILM peeling and panretinal laser coagulation (PRLC) (n=81); or CSTV combined with ILM peeling, PRLC and phaco (n=69). Preoperatively, ELISA was used to determine blood endothelin-1 (ET1) and tumor necrosis factor alpha (TNF?), and platelet-derived growth factor (PDGF-BB) levels, and polymorphisms of PDGFB (rs1800818) and TNF? (rs1800629) were investigated by real-time polymerase chain reaction. Follow-up visits were at months 1, 3, 6 and 12 after surgery. Multivariate logistic regression analysis was used to develop a model in Statistica 10 (GLZ; StatSoft, Tulsa, OK, USA).

Results: The regression analysis showed no association of age, gender, severity and duration of T2DM, glucose and glycated hemoglobin (НbA1c) levels, diabetic retinopathy (DR) stage and severity on the ETDRS scale, central retinal thickness (CRT0), or blood ЕТ1 level with post-surgical recurrent DMP within 12 months after surgery. Genotypes of TNF-? (rs1800629) and PDGFB (rs1800629) polymorphisms, and blood PDGF-BB and TNF? levels were found to be significant predictors of the presence or absence of recurrent DMP. The probability of developing recurrent DMP was directly related to the TNF? rs1800629 polymorphism and blood PDGF-BB and TNF? levels, and inversely related to the PDGFB rs1800818 polymorphism. The percentage contributions of selected independent variables in predicting the dependent variable were found to be as follows: TNF? rs1800629, 90.25%; PDGFB rs1800818, 9.57%; PDGF-BB, 0.15%; and TNF?, 0.03%. Performance measures of the model were satisfactory, with Area under Curve (AUC) = 0.993; -2*log (Likelihood) = 197.80; ?2 = 110.15 (p < 0.001).

Conclusion: TNF-? (rs1800629) and PDGFB (rs1800629) polymorphisms, and blood PDGF-BB and TNF? levels were predicting factors for recurrent DMP within 12 months after surgery.

Keywords: diabetic maculopathy, type 2 diabetes mellitus, surgical treatment, recurrence, rs1800629, rs1800818, PDGF-BB, TNF?



1.Balashevich LI, Izmailov AS. [Diabetic ophthalmopathy]. St. Petersburg: Chelovek;  2012. Russian.

2.Xiao K, Dong YC, Xiao XG, Liang SZ, Wang J, Qian C, Wan GM. Effect of pars plana vitrectomy with or without cataract surgery in patients with diabetes: a systematic review and meta-analysis. Diabetes Ther. 2019 Oct;10(5):1859-1868. doi: 10.1007/s13300-019-0672-9.

3.Hu XY, Liu H, Wang LN, Ding YZ, Luan J. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a Meta-analysis. Int J Ophthalmol. 2018 Nov 18;11(11):1848-55. doi: 10.18240/ijo.2018.11.18.

4.Jackson TL, Nicod E, Angelis A, Grimaccia F, Pringle E, Kanavos P. PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina. 2017 May;37(5):886-95. doi: 10.1097/IAE.0000000000001280.

5.Rinaldi M, dell'Omo R, Morescalchi F, Semeraro F, Gambicorti E, Cacciatore F, Chiosi F, Costagliola C. ILM peeling in nontractional diabetic macular edema: review and metanalysis. Int Ophthalmol. 2018 Dec;38(6):2709-14. doi: 10.1007/s10792-017-0761-6.

6.Norihito Doi, Taiji Sakamoto. Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes. Graefes Arch Clin Exp Ophthalmol. 2012;250:71-8.

7.Panchenko Yu. Effectiveness off different methods of surgical treatment of diabetic maculopathy in patients with type 2 diabetes. American Science Journal. 2019;28(2):27-34.

8.Panchenko Yu. Possibilities and effectiveness of cataract phacoemulsification, closed subtotal vitrectomy and panretinal laser coagulation in diabetic maculopathy treatment in patients with type 2 diabetes. East European Science Journal. 2019;7(47 part 2):50-6.

9.Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: Breaking the barrier. Pathophysiology. 2017;24(4):229-41. 

10.Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O'Neal DN, Januszewski AS. Biomarkers in Diabetic Retinopathy. Rev Diabet Stud. 2015 Spring-Summer;12(1-2):159-95. 

11.Mogilevskyy S.Iu., Panchenko Iu.O., Ziablytsev S.V. New risk factors for post-surgical recurrent diabetic maculopathy in type 2 diabetus mellitus. Journal of Ophthalmology (Ukraine). 2019;5(490):9-17.

12.Kamoi K, Takeda K, Hashimoto K, Tanaka R, Okuyama S. Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus. Curr Diabetes Rev. 2013 May;9(3):209-17. 

13.Diep TM, Tsui I. Risk factors associated with diabetic macular edema. Diabetes Res Clin Practice. 2013 Jun;100(3):298-305.

14.Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-? and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016 Oct;86:100-109. doi: 10.1016/j.cyto.2016.06.028.

15.IRS1 – Insulin receptor substrate 1 – Homo sapiens (Human) – IRS1 gene & protein". www.uniprot.org. Retrieved 2016-04-21.

16.Takaguri A. [Elucidation of a new mechanism of onset of insulin resistance: effects of statins and tumor necrosis factor-? on insulin signal transduction]. Yakugaku Zasshi. 2018;138(11):1329-1334. doi: 10.1248/yakushi.18-00116. Japanese.

17.Jamil K, Jayaraman A, Ahmad J, Joshi S, Yerra SK. TNF-alpha -308G/A and -238G/A polymorphisms and its protein network associated with type 2 diabetes mellitus. Saudi J Biol Sci. 2017 Sep;24(6):1195-1203. doi: 10.1016/j.sjbs.2016.05.012

18.Liu ZH, Ding YL, Xiu LC, Pan HY, Liang Y, Zhong SQ, Liu WW, Rao SQ, Kong DL. A meta-analysis of the association between TNF-? -308G>A polymorphism and type 2 diabetes mellitus in Han Chinese population. PLoS One. 2013;8(3):e59421. doi: 10.1371/journal.pone.0059421.

19.Dhamodharan U, Viswanathan V, Krishnamoorthy E, Rajaram R, Aravindhan V. Genetic association of IL-6, TNF-? and SDF-1 polymorphisms with serum cytokine levels in diabetic foot ulcer. Gene. 2015 Jul 1;565(1):62-7. doi: 10.1016/j.gene.2015.03.063.

20.Doody NE, Dowejko MM, Akam EC, Cox NJ, Bhatti JS, Singh P, Mastana SS. The role of TLR4, TNF-? and IL-1? in type 2 diabetes mellitus development within a North Indian population. Ann Hum Genet. 2017 Jul;81(4):141-146. doi: 10.1111/ahg.12197.

21.Sesti LF, Crispim D, Canani LH, Polina ER, Rheinheimer J, Carvalho PS, Gross JL, Santos KG. The -308G>A polymorphism of the TNF gene is associated with proliferative diabetic retinopathy in Caucasian Brazilians with type 2 diabetes. Invest Ophthalmol Vis Sci. 2015 Jan 29;56(2):1184-90. doi: 10.1167/iovs.14-15758.

22.Luna GI, da Silva IC, Sanchez MN. Association between -308G/A TNFA Polymorphism and Susceptibility to Type 2 Diabetes Mellitus: A Systematic Review. J Diabetes Res. 2016;2016:6309484.

23.Mogilevskyy SIu, Panchenko IuO, Ziablytsev SV. Predicting the risk of diabetic retinopathy-assosiated macular edema in patients with type 2 diabetes mellitus. Journal of Ophthalmology (Ukraine). 2019;3(488):3-8.

24.Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, Chaudhry AG, Hackett SF, Campochiaro PA. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci. 2002;43:2001-6.

25.Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, Aiello LP, Kern TS, King GL. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nature Med. 2009;15:1298-306.

26.Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Ding L, Kim JW, Kim H, He Y, Adams RH, and Koha GY. Plastic roles of pericytes in the blood-retinal barrier. Nat Commun. 2017 May 17;8:15296.

27.Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res. 2009 Feb;34(2):152-61.

28.Kitahara H, Kajikawa S, Ishii Y, Yamamoto S, Hamashima T, Azuma E, Sato H, Matsushima T, Shibuya M, Shimada Y, Sasahara M. The Novel Pathogenesis of Retinopathy Mediated by Multiple RTK Signals is Uncovered in Newly Developed Mouse Model. EBioMedicine. 2018 May;31:190-201.


The authors certify that they have no conflicts of interest in the subject matter or materials discussed in this manuscript.